Ocular Applications of Povidone-Iodine

Isenberg, Sherwin J.; Apt, Leonard; Campeas, D.

doi:10.1159/000057733

Cited by 38 publications

(24 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4,5 By the early 1990s, the use of topical povidone-iodine in preoperative conjunctival and eyelid preparation gained popularity, and it remains the most widely accepted ocular disinfectant. [6][7][8] Povidone-iodine has been found to be effective against a wide range of bacteria, fungi, protozoa, and viruses. [9][10][11] However, as with antibiotic agents, resistance, regardless of its mechanism (eg, true or pseudo), can be a concern with disinfectant agents and must be monitored periodically.…”

Section: Discussionmentioning

confidence: 99%

Effect of povidone–iodine concentration and exposure time on bacteria isolated from endophthalmitis cases

Hosseini

Ashraf

Saleh

et al. 2012

Journal of Cataract and Refractive Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of povidone–iodine concentration and exposure time on bacteria isolated from endophthalmitis cases

Hosseini

Ashraf

Saleh

et al. 2012

Journal of Cataract and Refractive Surgery

View full text Add to dashboard Cite

show abstract

“…35---37 Povidone-iodine has a broad antimicrobial spectrum in vitro and effectively kills bacteria, fungi, viruses and protozoa. 35,36 A study by Pelletier et al investigated a topical combination agent that contained 0.4% povidone-iodine as an anti-viral and 0.1% dexamethasone as a potent steroid. 37 The expectation of the study was to ''effectively treat both the inflammatory and infectious components of acute adenoviral conjunctivitis by decreasing the symptomatic period following infection, shortening the duration of viral shedding and reducing the potential for infectious transmission.''…”

Section: Introductionmentioning

confidence: 99%

Epidemic keratoconjunctivitis: A review of current concepts in management

Pihos

2013

Journal of Optometry

View full text Add to dashboard Cite

Epidemic keratoconjunctivitis (EKC) is an ocular surface infection caused by adenovirus. To date, there are no approved topical antiadenoviral therapeutics to treat EKC. Recent research reveals that treatment with topical corticosteroids for symptomatic relief of EKC enhances adenovirus replication and delays cell shedding from the ocular surface which delays adenovirus elimination. The current management of EKC largely revolves around accurate diagnosis of the condition and implementation of disinfection protocol to prevent its spread. Development of an effective antiviral treatment that addresses inflammation and does not prolong viral shedding would provide significant benefit. The literature reports on a variety of therapeutics that could potentially satisfy this deficiency. Topical ganciclovir and povidoneiodine combination drops have shown the most recent potential, but both therapeutics need to be investigated in larger scale studies. Until an antiadenoviral option is produced, the treatment of EKC should maintain a judicious case by case approach aiming to contain its dissemination and prevent visual consequences. Queratoconjuntivitis epidémica: revisión de los conceptos actuales de tratamientoResumen La queratoconjuntivitis epidémica (QCE) consiste en una infección de la superficie ocular causada por adenovirus. Hasta la fecha no existen terapias antiadenovíricas aprobadas para tratar la QCE. Las investigaciones recientes revelan que el tratamiento con corticoesteroides tópicos para un alivio sintomático de la QCE aumenta la replicación del adenovirus y retrasa la descamación de células en la superficie ocular, retardando la eliminación del virus. El tratamiento actual de la QCE gira alrededor del diagnóstico preciso sobre la condición clínica y la introducción de un protocolo de desinfección que impida su diseminación. El desarrollo de un tratamiento antivírico eficaz que trate la inflamación y no retrase la eliminación vírica supondría un beneficio considerable. La literatura reporta gran variedad de terapias que podrían satisfacer potencialmente esta deficiencia. La aplicación de gotas tópi-cas con una combinación de ganciclovir y iodina-povidona ha demostrado recientemente su potencial, aunque ambas terapias precisan investigarse mediante estudios a gran escala. Hasta A.M. Pihos que aparezca una opción antiadenovírica el tratamiento de la QCE debería realizarse utilizando un enfoque caso a caso, a fin de contener su diseminación y prevenir consecuencias visuales.

show abstract

“…5 This combination suspension was developed to eliminate the organisms responsible for infection while simultaneously reducing the inflammatory damage that often accompanies ocular surface infection. Successful use has been reported in human adenoviral conjunctivitis.…”

mentioning

confidence: 99%